Spirodiketopiperazine-based CCR5 antagonist: Discovery of an antiretroviral drug candidate

被引：9

作者：

Nishizawa, Rena ^{[1
]}

Nishiyama, Toshihiko ^{[1
]}

Hisaichi, Katsuya ^{[1
]}

Minamoto, Chiaki ^{[1
]}

Matsunaga, Naoki ^{[1
]}

Takaoka, Yoshikazu ^{[1
]}

Nakai, Hisao ^{[1
]}

Jenkinson, Stephen ^{[3
]}

Kazmierski, Wieslaw M. ^{[3
]}

Tada, Hideaki ^{[2
]}

Sagawa, Kenji ^{[2
]}

Shibayama, Shiro ^{[2
]}

Fukushima, Daikichi ^{[2
]}

Maeda, Kenji ^{[4
,5
]}

Mitsuya, Hiroaki ^{[4
,5
]}

机构：

[1] Ono Pharmaceut Co Ltd, Med Chem Res Lab, Osaka 6188585, Japan

[2] Ono Pharmaceut Co Ltd, Exploratory Res Lab, Ibaraki 300424, Japan

[3] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC 27709 USA

[4] Kumamoto Univ, Sch Med, Dept Internal Med 2, Kumamoto 8600811, Japan

[5] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 04期

关键词：

CCR5; Chemokine; Anti-HIV; CHEMOKINE RECEPTOR; HIV-1; INFECTION; VIRAL ENTRY; CORECEPTOR; COFACTOR; POTENT;

D O I：

10.1016/j.bmcl.2010.12.109

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Following the discovery that hydroxylated derivative 3 (Fig. 1) was one of the oxidative metabolites of the original lead 1, it was found that hydroxylated compound 4 possesses higher in vitro anti-HIV potency than the corresponding non-hydroxylated compound 2. Structural hybridation of 4 with the orally available analog 5 resulted in another orally-available spirodiketopiperazine CCR5 antagonist 6a that possesses more favorable pharmaceutical profile for use as a drug candidate. (c) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1141 / 1145

页数：5

共 50 条

[31] Evolution of coreceptor utilization to escape CCR5 antagonist therapy
Zhang, Jie
Gao, Xiang
Martin, John
Rosa, Bruce
Chen, Zheng
Mitreva, Makedonka
Henrich, Timothy
Kuritzkes, Daniel
Ratner, Lee
VIROLOGY, 2016, 494 : 198 - 214
[32] Rapamycin enhances the antiviral activity of CCR5 antagonist Vicriviroc
Latinovic, Olga
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 : 92 - 92
[33] Preparation and Activities of Macromolecule Conjugates of the CCR5 Antagonist Maraviroc
Asano, Shigehiro
Gavrilyuk, Julia
Burton, Dennis R.
Barbas, Carlos F., III
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (02): : 133 - 137
[34] Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy
Bowler, S.
Siriwardhana, C.
Mitchell, B. L.
D'Antoni, M. L.
Ogata-Arakaki, D.
Souza, S.
Yee, R.
Gangcuangco, L. M. A.
Chow, D. C.
Ndhlovu, L. C.
Shikuma, C.
HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (4-5) : 123 - 129
[35] Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
Soulie, Cathia
Malet, Isabelle
Lambert-Niclot, Sidonie
Tubiana, Roland
Thevenin, Monique
Simon, Anne
Murphy, Robert
Katlama, Christine
Calvez, Vincent
Marcelin, Anne-Genevieve
AIDS, 2008, 22 (16) : 2212 - 2214
[36] Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5
Nishikawa, M
Takashima, K
Nishi, T
Furuta, RA
Kanzaki, N
Yamamoto, Y
Fujisawa, J
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) : 4708 - 4715
[37] Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5
Dawson, John R. D.
Kufareva, Irina
BIOPHYSICAL JOURNAL, 2023, 122 (03) : 185A - 185A
[38] A dual CCR2/CCR5 chemokine antagonist, BMS-813160?
Norman, Peter
EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (12) : 1919 - 1924
[39] The discovery and exploratory development of Maraviroc (UK-427,857): A novel CCR5 antagonist for the treatment of HIV
Hitchcock, C. A.
RETROVIROLOGY, 2005, 2 (Suppl 1)
[40] The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV
CA Hitchcock
Retrovirology, 2

← 1 2 3 4 5 →